PARIPEX - INDIAN JOURNAL OF RESEARCH | Volume-9 | Issue-3 | March - 2020 | PRINT ISSN No. 2250 - 1991 | DOI : 10.36106/paripex

| CL<br>SEI<br>ST                    |  | ORIGINAL RESEARCH PAPER   |   | General Medicine   |  |  |
|------------------------------------|--|---|---|--|--|--|
|                                    |  | INICAL PROFILE AND CORRELATION OF<br>RUM BNP LEVEL AT ADMISSION WITH ICU<br>AY DURATION IN PATIENTS OF ACUTE<br>COMPENSATED HEART FAILURE   |   | <b>KEY WORDS:</b> HF-Heart<br>Failure, BNP-Brain Natriuretic<br>peptide, HTN-Hypertension<br>DM-Diabetes Mellitus,<br>IHD-Ischemic Heart Disease |  |  |
| Dr Sagar Desai                     |  | DM-Cardiology Assistant Professor, General Medicine Department,<br>S.Nijalingappa Medical College and HSK Hospital, Bagalkot (Karnataka)  |   |  |  |  |
| Dr Ayush M<br>Patel*               |  | Post Graduate Student, General Medicine Department, S.Nijalingappa<br>Medical College and HSK Hospital, Bagalkot (Karnataka) *Corresponding<br>Author   |   |  |  |  |
| ABSTRACT                           | <ul> <li>BACKGROUNDS: Serum BNP levels have been established for diagnosis of HF in proportion to severity of symptoms, degree of LV dysfunction with other comorbidity and predict morbidity and mortality in HF pts.</li> <li>Methods: A Case series descriptive study of 50 patients admitted in ICU of HSK Hospital, Bagalkot in duration of 3 months of study period with HF (according to symptoms and LV dysfunction) and perform spot test of serum BNP level(reference value &gt;100pg/ml) and correlate with pts ICU stay duration.</li> <li>Results: Study comprised of 50 HF pts. In this study mean age of 63 yr pts and their association distribution with BNP level was 1100 pg/ml and 4 days of mean ICU stay by using Pearson Chi-Square test (X2-0.996b). High level of BNP with other comorbities also prolong the duration of ICU stay.</li> <li>Conclusion: This Study shows that in patients with heart failure, raise BNP level is associated with long ICU stay in hospital. So, it can use as predictor for in hospital treatment. Further this Study shows possibility of associated complications with various comorbidities in heart failure</li> <li>patients, who had raised BNP levels. So, it can use as a prognostic indicator.</li> </ul> |   |   |  |  |  |
| <ul> <li>He an de is ab</li> </ul> | nount of oxygenated blo<br>mands and to collect bl<br>complex clinical s<br>normalities of Left ve   | ency of heart to pump sufficient<br>od to organs to meet metabolic<br>ood from organs". <sup>1</sup> Heart failure<br>yndrome characterized by<br>ntricular function and neuro-<br>eart failure is defined by the | Hospital. <ul> <li>Sample size:50</li> </ul> Inclusion criteria | hs (May-July-2019)<br>Il patients admitted in ICU of HSK<br>I in ICU with heart failure symptoms   |  |  |

All 50 patients admitted in ICU with heart failure symptoms and left ventricular dysfunction during the study period were included in the study.

# • Exclusion criteria

Patients with other causes of raised BNP levels like Acute or Chronic renal failure, Chronic obstructive pulmonary disease, Pulmonary embolism, Pneumonia, Sepsis, Liver cirrhosis, Hyperthyroidism were excluded.

#### • Statistical Analysis:

The data obtained was compiled and analyzed using Epi-info version 6.0 with diagnosed accuracy of BNP was evaluated by calculating Pearson Chi-Square test and results were shown in % and tables with 95% confidence interval.

# • RESULTS DISCUSSION:

# Table 1: shows age distribution according to gender

| Group   | Age    | Male | Female | Total |                        |
|---------|--------|------|--------|-------|------------------------|
| Cases   | 26-50  | 4    | 4      | 8     | df=3                   |
|         | 51-75  | 18   | 21     | 39    | X <sup>2</sup> =0.996b |
|         | 76-100 | 1    | 1      | 2     | P=0.802                |
|         | >100   | 1    | 0      | 1     |                        |
|         |        | 24   | 26     | 50    |                        |
| Control | <25    | 1    | 0      | 1     |                        |
|         | 26-50  | 8    | 7      | 15    |                        |
|         | 51-75  | 18   | 11     | 29    |                        |
|         | 76-100 | 3    | 2      | 5     |                        |
|         |        | 30   | 20     | 50    |                        |
| Total   |        | 54   | 46     | 100   |                        |

- Table 1 shows age distribution according to gender.
- In it 50 cases included who admitted with heart failure symptoms with LV dysfunction and 50 controls included who admitted with other symptoms or disease.
- In cases there is no significant variation in gender and belong to age group 51-75 yrs.

# **OBJECTIVES OF THE STUDY:**

pressures.<sup>10</sup>

vasorelaxation and natriuresis.<sup>°</sup>

• The goal of this study is to evaluate the clinical profile and explore the correlation between serum BNP levels at presentation at hospital and duration of ICU stay in patients, who presented with heart failure (symptoms and left ventricular dysfunction). MATERIALS AND METHODS:

presence of typical symptoms such as dyspnea, fatigue

and/or fluid retention due to cardiac dysfunction. These

typical, yet non-specific symptoms can make heart failure difficult to diagnose.  $^{\rm s}$  Inaccurate emergency diagnosis of

elderly patients with acute respiratory failure was shown

to be as high in Study Group.<sup>4</sup> These missed diagnoses

were associated with highly significant increases in

mortality, and highlighted the need for diagnostic tools

with high specificity and sensitivity that can be accessed

Brain Natriuretic Peptide [BNP] exclusively ventricular

derived hormone, so failing in ventricular activity stimulates production of more BNP.<sup>6</sup> The brain natriuretic

peptide (BNP) gene is activated in cardiomyocytes when myocardial wall stress is increased by an overload of volume or pressure.<sup>7</sup> The resulting precursor peptide

(BNP) is cleaved into two parts: active BNP, and inactive Nterminal (NT)-BNP, which are released into the circulation. BNP, as well as various degradation products of BNP, can also be found in the bloodstream.<sup>8</sup> In cases of heart failure, a large increase in the usually low BNP levels occurs, leading to positive downstream effects, including

So, circulating concentration of BNP are increased in heart failure in proportion to severity of symptoms, degree of Left ventricular dysfunction and cardiac filling

quickly in a busy ED environment.<sup>5</sup>

- Study design: A case series descriptive study.
- **Study setting:** ICU of S. N. Medical College and HSK Hospital, Bagalkot (Karnataka).

80

#### PARIPEX - INDIAN JOURNAL OF RESEARCH | Volume-9 | Issue-3 | March - 2020 | PRINT ISSN No. 2250 - 1991 | DOI : 10.36106/paripex

| Table 2 showing co-morbidities association with groups |       |        |                              |  |
|--|-------|--------|------------------------------|--|
| Parameter  | NO(%) | YES(%) |                              |  |
| HTN-<br>Control  | 72    | 28     | P<0.663                      |  |
| HTN- Case  | 68    | 32     | df=1, X <sup>2</sup> =0.190a |  |
| DM- Control  | 62    | 38     | P<0.418                      |  |
| DM- Case   | 54    | 46     | df=1, X <sup>2</sup> =0.657a |  |
| IHD- Control   | 92    | 8      | P<0.617                      |  |
| IHD- Case  | 68    | 32     | df=1, X <sup>2</sup> =0.250a |  |

Table 2 shows -Comorbidities like HTN, DM, IHD have significantly association with cases group who are heart failure patients than other group.

# Table 3 showing the Mean ± SD and association distribution of Age, BNP and ICU stay.

| Parameter          | Mean    | SD±      |           |
|--------------------|---------|----------|-----------|
| Age- Control       | 56.42   | 14.983   | P<0.802   |
| Age- Case          | 63.08   | 12.227   | df=3      |
| BNP- Control       | 29.46   | 29.488   | X2=0.996b |
| BNP- Case          | 1112.98 | 1252.652 |           |
| ICU Stay - Control | 2.20    | 0.881    |           |
| ICU Stay- Case     | 4.16    | 1.963    |           |

Table 3 shows – Mean value of both study groups with parameters like Age, BNP, ICU stay duration.

In Cases it shows significant elevation in BNP value and also ICU duration prolongation compare with control group.

# Table 4 shows-Clinical profile and correlation of BNP level and ICU stay

| BNP       | Total | Associate | Duration of | Complications   |
|-----------|-------|-----------|-------------|-----------------|
| Level     | Cases | d co-     | ICU Stay in |                 |
| [pg/ml]   |       | morbidity | days[Mean]  |                 |
| 101-200   | 12    | 4         | 2           | 0               |
| 201-500   | 10    | 4         | 2.5         | 0               |
| 501-1000  | 11    | 5         | 4           | 1               |
| 1000-2000 | 9     | 7         | 5.5         | 3[1 case death] |
| >2000     | 8     | 7         | 7           | 5[3 case death] |

- Study shows significant rise in BNP level leads to prolong ICU stay as well as increased risk of complications [including death].
- This study also suggestive of significant association between comorbidities and complications as well as direct correlation with Raised BNP level and ICU stay duration.
- Result of the present study indicates the BNP level at admission predict the ICU stay duration and in-hospital complications of heart failure patients.
- Previous reference study shows frequent changes in BNP level during hospitalization due to therapy[treatment] and monitoring of BNP gives proper clue about morbidity and mortality.so it can consider a limitation for present study.

# CONCLUSION:

- This Study shows that in patients with heart
- failure, raise BNP level is associated with long ICU stay in hospital. So, it can use as predictor for in hospital treatment.
- Further this Study shows possibility of associated complications with various co-morbidities in heart failure patients who had raise BNP levels. So it can use as a prognostic indicator.

#### **REFERENCES:**

1. Nieminen MS, Bohm M, Cowie MR, et al: Executive summary of the guidelines
www.worldwidejournals.com

on the diagnosis and treatment of acute heart failure:The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26:384–416

- Nohria A, Mielniczuk LM, Stevenson LW: Evaluation and monitoring of patients with acute heart failure syndromes. Am J Cardiol 2005;96:32G–40G
- Sudoh T, Kangawa K, Minamino N, et al: A new natriuretic peptide in porcine brain. Nature 1988;332:78–81
- 4. Mukoyama M, Nakao K, Hosoda K, et al: Brain natriuretic peptide as a novel cardiac hormone in humans: Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87:1402–1412 5. RuskoahoH:Cardiachormonesasdiagnostic tools in heart failure. Endocr Rev 2003;24:341–356
- de Lemos JA, McGuire DK, Drazner MH: Btype natriuretic peptide in cardiovascular disease.Lancet 2003;362:316–322
- Yandle TG, Richards AM, Gilbert A, et al: Assay of brain natriuretic peptide (BNP) in human plasma: Evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 1993; 76:832–838
- Hawkridge AM, Heublein DM, Bergen HR III, et al: Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad SciUSA2005; 102: 17442–17447
- Kinnunen P, Vuolteenaho O, Ruskoaho H: Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: Effect of stretching. Endocrinology 1993;132:1961–1970
- Espiner EA, Richards AM, Yandle TG, et al: Natriuretic hormones. Endocrinol Metab Clin North Am 1995;24:481–509